Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial
Kiyoshi Suzuma, Toshinori Murata, Masahiko Shimura, Shigeo Yoshida et autres
PURPOSE: In the pivotal PHOTON trial of patients with diabetic macular edema (DME), aflibercept 8 mg administered every 12 (8q12) and 16 (8q16) weeks demonstrated similar visual and anatomic outcomes with no new safety signals to aflibercept 2 mg every 8 weeks …
jp, us, ch, de (code pays fourni par la source)
0 citations
Japanese Journal of Ophthalmology